DRY CHEMISTRY IN PRECISION MEDICINE (Q2044561): Difference between revisions
Jump to navigation
Jump to search
(Created claim: summary (P836): INTRODUCTION OF PHARECH PHARMACOGENETICS, BORN IN 2010, NOW WITH A MARKET SHARE IN ITALY OF 70 %, IT IS AN ABSOLUTE LEADER IN THE FIELD OF PHARMACOGENETICS AND PERSONALISATION OF TREATMENT. PRIORITY AREA OF APPLICATION OF THE RESEARCH DEVELOPED BY DIPECH PHARMACOGENETICS ÃO CANCER IS A MAJOR PRIORITY. THE COMPANY SUPPORTS ITS OWN RESEARCH THROUGH THE SALE AND DEVELOPMENT OF PHARMACOGENETIC TESTS USED IN PERSONALISED AND GENETIC MEDICINE BASED O...) |
(Changed an Item) |
||
| Property / programme | |||
| Property / programme: Marche - ERDF / rank | |||
Normal rank | |||
Revision as of 07:02, 24 March 2020
Project in Italy financed by DG Regio
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | DRY CHEMISTRY IN PRECISION MEDICINE |
Project in Italy financed by DG Regio |
Statements
56,600.0 Euro
0 references
113,200.0 Euro
0 references
50.0 percent
0 references
2 August 2016
0 references
28 June 2018
0 references
24 August 2018
0 references
DIATECH PHARMACOGENETICS S.R.L. A SOCIO UNICO
0 references
Q286403 (Deleted Item)
0 references
43°31'19.13"N, 13°14'39.77"E
0 references
INTRODUZIONE DIATECH PHARMACOGENETICS, NATA NEL 2010, OGGI CON UNA QUOTA DI MERCATO IN ITALIA DEL 70% Ê LEADER ASSOLUTA NEL SETTORE DELLA FARMACOGENETICA E DELLA PERSONALIZZAZIONE DELLE CURE. PRIORITARIO AMBITO DI APPLICAZIONE DELLE RICERCHE SVILUPPATE DA DIATECH PHARMACOGENETICS Ê QUELLO ANTITUMORALE. L`AZIENDA SOSTIENE LA PROPRIA RICERCA GRAZIE ALLA VENDITA E ALLO SVILUPPO DI TEST FARMACOGENETICI IMPIEGATI NELLA MEDICINA PERSONALIZZATA E GENETICA PARTENDO, PER PRIORITà , DALLE CURE PIù INVASIVE: QUELLE ANTITUMORALI. GRAZIE AI KIT FARMACOGENETICI SVILUPPATI DA DIATECH PHARMACOGENETICS Ê POSSIBILE, INFATTI, PERSONALIZZARE I TRATTAMENTI CHEMIOTERAPICI E RADIOTERAPICI, RENDENDOLI PIù EFFICACI E RIDUCENDONE GLI EFFETTI COLLATERALI. LE SOLUZIONI DI DIATECH PHARMACOGENETICS INTERESSANO, OLTRE IL COLON, ANCHE I TUMORI DEI POLMONI E DELLA PELLE; I TUMORI CEREBRALI; L`AMBITO CARDIOVASCOLARE. OGGI I TEST FARMACOGENETICI SI STANNO IMPONENDO COME OBBLIGATORI NELL¿USO DEI FARMACI ANTITUMO (Italian)
0 references
INTRODUCTION OF PHARECH PHARMACOGENETICS, BORN IN 2010, NOW WITH A MARKET SHARE IN ITALY OF 70 %, IT IS AN ABSOLUTE LEADER IN THE FIELD OF PHARMACOGENETICS AND PERSONALISATION OF TREATMENT. PRIORITY AREA OF APPLICATION OF THE RESEARCH DEVELOPED BY DIPECH PHARMACOGENETICS ÃO CANCER IS A MAJOR PRIORITY. THE COMPANY SUPPORTS ITS OWN RESEARCH THROUGH THE SALE AND DEVELOPMENT OF PHARMACOGENETIC TESTS USED IN PERSONALISED AND GENETIC MEDICINE BASED ON, FOR PRIMARITARED, THE TREATMENTS THAT ARE INVASIVE. ANTI-CANCER. AS A RESULT OF THE PHARMACOGENETIC KITS DEVELOPED BY DIOTECH PHARMACOGENETICS, IT IS POSSIBLE TO PERSONALISE CHEMOTHERAPY AND RADIOTHERAPEUTIC TREATMENTS, MAKING THEM EFFECTIVE AND REDUCING THEIR SIDE EFFECTS. PHARMACOGENETICS SOLUTIONS ALSO AFFECT LUNG AND SKIN CANCERS BEYOND THE COLON; BRAIN TUMOURS; CARDIOVASCULAR FIELD. NOWADAYS, THE PHARMACOGENETIC TESTS ARE BEING IMPOSED AS A MANDATORY REQUIREMENT FOR THE USE OF ANTIMUM DRUGS. (English)
0 references
Identifiers
B43G17000080007
0 references